Why Corcept Therapeutics (CORT) Is Up 8.5% After First-in-Class Lifyorli FDA Cancer Approval – And What's Next [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior therapies including bevacizumab. The approval, based on the ROSELLA trial showing meaningful overall and progression-free survival benefits without biomarker selection, introduces the first approved selective glucocorticoid receptor antagonist and a new treatment option in a setting with limited alternatives. We'll now examine how Lifyorli's first-in-class approval, backed by the ROSELLA survival data, reshapes Corcept's investment narrative and risk profile. Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Corcept Therapeutics Investment Narrative Recap To own Corcept today, you need to believe that its cortisol-modulation platform can transition the story beyond Korlym and its authorized generic, while funding an expanding pipeline without permanently compr
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPR Newswire
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire
- CORT Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Corcept Therapeutics Incorporated Securities Lawsuit -- The Gross Law FirmPR Newswire
- ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORTGlobeNewswire
- Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade) [Seeking Alpha]Seeking Alpha
CORT
Earnings
- 2/24/26 - Miss
CORT
Sec Filings
- 3/27/26 - Form 4
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form 144
- CORT's page on the SEC website